目的 观察与评价药物基因检测指导儿童哮喘个体化治疗的临床疗效。方法 选取2019年1-4月福建省福州儿童医院变态反应科门诊非急性发作期轻-中度过敏性哮喘儿童, 根据哮喘药物基因检测结果, 分为吸入型糖皮质激素治疗实验组和白三烯调节剂治疗实验组各20例, 进行相应的哮喘个体化治疗, 随访6个月, 分别与未进行基因检测给予吸入型糖皮质激素和白三烯调节剂治疗的对照组在呼出气一氧化氮(FeNO)、儿童哮喘控制测试(C-ACT)评分、肺功能FEV1%、PEF、FEF25%、FEF50%、FEF75%、呼吸道感染次数、儿童误学天数等指标进行比较分析。结果 1)吸入型糖皮质激素治疗实验组C-ACT评分和肺功能FEV1%、PEF、FEF25%指标疗效明显优于对照组, 差异有统计学意义(P<0.05);实验组FeNO和肺功能FEF50%、FEF75%指标与对照组差异无统计学意义(P>0.05)。2)白三烯调节剂治疗实验组C-ACT评分和肺功能FEV1%, PEF指标疗效明显优于对照组, 差异有统计学意义(P<0.05);实验组FeNO和肺功能FEF25%、FEF50%、FEF75%指标与对照组差异无统计学意义(P>0.05)。3)随访6月, 吸入型糖皮质激素治疗实验组感染次数和误学天数较对照组明显下降, 差异有统计学意义(t=4.461, 7.259, P<0.05), 白三烯调节剂治疗实验组与对照组间感染次数和误学天数差异无统计学意义(P>0.05)。结论 药物基因检测是实现哮喘个体化治疗的方向, 但目前国内临床相关资料有限, 有待大样本量研究以提供更可靠的临床数据。
Abstract
Objective To observe and evaluate the clinical efficacy of individualized treatment of childhood asthma under the guidance of pharmacogenetic testing. Methods Children with acute exacerbation of mild-moderate allergic asthma were enrolled in this study from Department of Allergy of Fuzhou Children's Hospital from January to April in 2019.According to the results of pharmacogenetic testing, children were divided into inhaled glucocorticoid experimental group and leukotriene modulator experimental group, with 20 cases in each group.Corresponding individual asthma treatment was carried out in two groups.The indicators were compared with the control group without genetic testing after follow-up for six months, including fractional exhaled nitric oxide(FeNO), children asthma control test(C-ACT) score, pulmonary function FEV1%, PEF, FEF25%, FEF50%, FEF75%, the number of respiratory infections and the number of children's missing days of school. Results 1) The inhaled glucocorticoid treatment experimental group was significantly better than the control group in C-ACT score and pulmonary function FEV1%, PEF, FEF25% indicators(P<0.05).FeNO and pulmonary function FEF50%, FEF75% in the experimental group were not significantly different from those in the control group (P>0.05).2)The leukotriene modulator treatment experimental group had a significantly better C-ACT score and pulmonary function FEV 1%, and the PEF index was significantly better than the control group(P<0.05).FeNO and lung function FEF25%, FEF50%, FEF75% in the experimental group were not statistically different from those in the control group (P>0.05).3) During the follow-up for 6 months, the number of infections and missing days of school in the inhaled glucocorticoid treatment experimental group were significantly lower than those in control group (t=4.461, 7.259, P<0.05), but the differences were not significant between the leukotriene modulator treatment experimental group and the control group(P>0.05). Conclusions Pharmacogenetic testing is the direction to achieve individualized treatment of asthma.Currently there are limited clinical data in China, so large sample studies are warranted to provide more reliable clinical data.
关键词
药物基因检测 /
儿童哮喘 /
个体化治疗
Key words
pharmacogenetic testing /
childhood asthma /
individualized treatment
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Thomsen SF, van derSluis S, Kyvik KO, et al.Estimates of asthma heritability in a large twin sample[J].Clin Exp Allergy, 2010, 40(7):1054-1061.
[2] 中华医学会儿科分会呼吸学组《中华儿科杂志》编辑委员会.儿童支气管哮喘诊断与防治指南(2016年版)[J].中华儿科杂志, 2016, 53(3):167-181.
[3] Chen Y, Wong GW, Li J.Environmental exposure and genetic predisposition as risk factors for asthma in China[J].Allergy Asthma Immunol Res, 2016, 8(2):92-100.
[4] Reddel HK, Bateman ED, Becker A, et al.A summary of the new GINA strategy:a roadmap to asthma control[J].Eur Respir J, 2015, 46(3):622-639.
[5] 鲍一笑, 白沙沙.儿童支气管哮喘易感基因相关研究进展[J].中华实用儿科临床杂志, 2019, 34(4):241-244.
[6] 李京阳, 鲍一笑.支气管哮喘的药物基因组学研究[J].国际儿科学杂志, 2012, 39(5):444-447.
[7] 荆小袁, 陆敏.哮喘个体化治疗的药物遗传学[J].国际儿科学杂志, 2016, 43(9):673-714.
[8] Hu C, Xun Q, Li X, et al.GLCCI1 variation is associated with asthma susceptibility and inhaled corticosteroid response in Chinese Han population[J].Arch Med Res, 2016, 47(2):118-125.
[9] Portelli M, Sayers I.Genetic basis for personalized medicine in asthma[J].Expert Rev Respir Med, 2012, 6(2):223-236.
[10] Baye TM, Abebe T, Wilke RA.Genotype-environment interactions and their translational implications[J].Per Med, 2011, 8(1):59-70.
[11] Tantisira KG, Lasky SJ, Harada M, et al.Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma[J].N Engl J Med, 2011, 365(13):1173-1183.
[12] Hosking L, Bleecker E, Ghosh S, et al.GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma[J].J Allergy Clin Immunol, 2014, 133(2):587-589.
[13] Mcgeachie MJ, Wu AC, Chang HH, et al.Predicting inhaled corticosteroid response in asthma with two associated SNPs[J].Pharmacogenomics J, 2013, 13(4):306-311.
[14] 丁颖, 陆敏, 董晓艳, 等.GLCCI1基因多态性对吸入型糖皮质激素治疗儿童哮喘疗效的影响[J].中国临床药学杂志, 2017, 26(6):353-358.
[15] 邱玉明, 李剑雄, 李慧, 等.153例汉族哮喘患者GCCLI1基因rs37973位点多态性及吸入糖皮质激素治疗反应[J].山东医药, 2016, 56(39):94-96.
[16] Tantisira KG, Lake S, Silverman ES, et al.Corticosteroid pharmacogenetics:association of sequence variants in CRHR1 with improved lungfunction in asthmatics treatedwith inhaled corticosteroids[J].Hum Mol Genet, 2014, 13(13):1353-1359.
[17] Koster ES, Maitland-van der Zee AH, Tavendale R, et al.FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid-treated asthmatic children[J].Allergy, 2011, 66(12):1546-1552.
[18] Tcheurekdjian H, Via M, De Giacomo A, et al.ALOX5AP and LTA4H SPN modify augmentation of bronchodilator responsiveness dy leukotriene modifiers in Latinos[J].Allergy Clin Immunol, 2010, 126(14):853-858.
[19] 蔡畅, 周美茜, 李玉萍, 等.支气管哮喘患者白三烯基因多态性与抗白三烯治疗的相关性研究[J].中华结核和呼吸杂志, 2011, 34(5):362-366.
[20] Kotani H, Kishi R, Mouri A, et al.Influence of leukotriene pathway polymorphisms on clinical responses to montelukast in Japanese patients with asthma[J].J Clin Pharm Ther, 2012, 37(1):112-116.
基金
2019年福州市科技计划项目课题(2019-S-78)
PDF(717 KB)
